Antitumor necrosis factor-α therapy is associated with reduced risk of thromboembolic events in hospitalized patients with inflammatory bowel disease

Journal of Clinical Gastroenterology

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/29EAOrP
via IFTTT